UCB is a global biopharma focused on severe diseases in two therapeutic areas: central nervous system and immunology operations.
The company is listed on the Euronext Brussels Stock Exchange and has its headquarters in Brussels, Belgium. It employs more than 8,500 people in more than 40 countries.
Financial Data
-
31st Dec 15 Source: CRO
- €136.4 million turnover
-
€461.9 million
profit - 120 employees
-
31st Dec 15 Source: CRO
- €136.4 million turnover
-
€461.9 million
profit - 120 employees
- 7 more years available »
Ranking
By Turnover
(€136.4 million)- 382nd in Top Companies
- 42nd in Health
- 44th in Pharma
By Employees
(120)- 664th in Top Companies
- 84th in Health
- 66th in Pharma
-
- 120
- €136.4 million
Employees
- Werner Kunz CEO/Managing Director